

# Molecular cloning and characterization of the gene coding for human complement protein factor B

(HLA class III antigen/serine proteinase/DNA sequence analysis/cosmid library/synthetic oligonucleotides)

R. DUNCAN CAMPBELL AND RODNEY R. PORTER

Medical Research Council Immunochemistry Unit, Department of Biochemistry, South Parks Road, Oxford OX1 3QU, United Kingdom

Contributed by R. R. Porter, March 21, 1983

**ABSTRACT** Four cosmid clones, each with an average insert size of 40 kilobase pairs and containing the factor B gene, were isolated from a human genomic DNA library. The clones were identified by hybridization with a 515-base-pair cDNA probe isolated by using a unique 17-base synthetic oligonucleotide probe from a human liver cDNA library. The cosmid clones were characterized by restriction endonuclease digestion and Southern blotting, and a partial restriction map of the DNA represented in the cosmids was constructed. The Bb portion of the factor B gene is about 4 kb in length. DNA sequence analysis has resulted in the determination of 3.3 kb of sequence at the 3' end of the gene. This region codes for amino acids 87–505 of Bb and includes the whole of the serine proteinase domain of the protein. The three active site residues of histidine, aspartic acid, and serine found at positions 267, 317, and 440 of the Bb sequence, respectively, lie on separate exons. Other functional regions within the serine proteinase domain are separated also by intervening sequences.

The major histocompatibility complex on human chromosome 6 is a highly polymorphic multigene system that encodes proteins known to have key roles in cell–cell recognition, especially those governing the functions of the immune system. The gene products fall into three major classes of antigen: class I and class II molecules are both integral cell-surface glycoproteins that are specified, respectively, by the loci for the major histocompatibility antigens HLA-A, -B, and -C and by the locus for HLA-DR, whereas class III molecules are components of the serum complement system—namely, factor B and the second and fourth components of complement, C2 and C4 (reviewed in refs. 1 and 2).

Factor B, a glycoprotein of  $M_r$  90,000, is a component of the alternative pathway of complement activation (3). It is cleaved by factor D in the presence of C3b into two fragments, Ba of  $M_r$  30,000 and Bb of  $M_r$  60,000 (4). The Bb fragment is the catalytically active component of the complex proteinases of the alternative pathway, C3 convertase C3bBb, and C5 convertase C3b<sub>n</sub>Bb (5). Amino acid sequence studies have shown factor B to be a novel type of serine proteinase with a catalytic chain of approximately twice the size of other known serine proteinases (6). Factor B is polymorphic, and at least 11 genetic variants have been identified on the basis of differences in electrophoretic mobility (7).

The availability of cDNA probes to class I (8–10) and class II (11–13) antigens has led to a better understanding of the molecular organization and genetic structure of the genes for these molecules. Although cDNA clones containing sequences coding for factor B have been isolated (14), little is known about the detailed molecular structure of the gene for this protein. To this end we have used a human factor B cDNA clone, isolated by using a synthetic oligonucleotide as probe, to screen human ge-

netic DNA cosmid libraries. Here we report the isolation and partial characterization of the factor B gene and the complete structure and sequence of that part of the gene specifying the serine proteinase domain of Bb.

## MATERIALS AND METHODS

**Synthesis of Oligonucleotide Probes.** The 14-base mixture of eight oligonucleotides and the unique 17-base oligonucleotide were synthesized by the solid-phase phosphotriester technique (15).

**Synthesis of cDNA.** The 14-base oligonucleotide mix was 5'-labeled by using [ $\gamma$ -<sup>32</sup>P]ATP and T4 polynucleotide kinase (16). Synthesis of single-stranded cDNA was based on the method of Wickens *et al.* (17) and was carried out by incubating 500 ng of the labeled oligonucleotide mix and 180  $\mu$ g of 18S RNA with 50 units of avian myeloblastosis virus reverse transcriptase (J. W. Beard) in 100  $\mu$ l at 42°C for 60 min. The mixture was incubated at 70°C for 20 min in 0.1 M NaOH/1 mM EDTA to degrade the RNA, precipitated with ethanol, and desalted on a Sephacryl S-300 column equilibrated in 0.2 M NaCl/1 mM EDTA/10 mM Tris, pH 7.4. The products of the reaction were analyzed under denaturing conditions on a 3% polyacrylamide gel.

**Isolation of cDNA Clones.** Approximately 30,000 clones of a human liver cDNA fragment library (18) were plated onto ampicillin plates, then transferred to Whatman 541 filter paper (19), and processed for hybridization as described by Gergen *et al.* (20). Filters were treated prior to hybridization (prehybridized) as described by Carroll and Porter (18), then hybridized for 16 hr at 46°C in solution containing the end-labeled unique 17-base oligonucleotide probe (2 ng/ml;  $8 \times 10^5$  cpm/ml). After successive washes at 4°C (1 hr) and 46°C (30 min), the filters were dried in air and autoradiographed at -70°C overnight.

**Isolation of Genomic Clones.** Approximately 200,000 clones from each of two cosmid libraries constructed by F. G. Grosveld *et al.* (21) using placental DNA partially digested with *Mbo* I were plated onto nitrocellulose filters. Replicas were prepared and processed for colony hybridization as described by Grosveld *et al.* (22). Filters were prehybridized and hybridized at 42°C in buffer containing 50% formamide (23).

The 515-base-pair (bp) insert of the factor B cDNA clone, FB1, was nick-translated to a specific activity of  $\approx 10^8$  cpm/ $\mu$ g of DNA (24). The hybridization mix contained  $2$ – $5 \times 10^5$  cpm/ml. After hybridization for 20 hr, the filters were washed as described by Carroll and Porter (18).

**Preparation and Analysis of Cloned DNA.** Plasmid (25) and cosmid (22) DNA were extracted from bacterial colonies by standard procedures. Partial characterization of the cosmids was achieved by a series of single, double, and triple digests and by separation of the fragments on agarose gels. DNA fragments

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Abbreviations: C2, C3, and C4, second, third, and fourth components of complement; bp, base pair; kb, kilobase pair.


were blotted onto nitrocellulose filters as described by Wahl *et al.* (26) and hybridized with either the factor B cDNA probe or the cosmid vector as probe.

Restriction fragments from the cosmid DNA found to hybridize with the cDNA probe were subcloned into the pAT153/*Pvu* II/8 plasmid vector as follows. A *Bgl* II digest and a *Sma* I digest were ligated into the *Bam*HI and *Pvu* II sites of the vector, respectively, and clones containing inserts corresponding to the 0.4-kilobase (kb) and 2.6-kb *Bgl* II fragments and the 11-kb *Sma* I fragment were detected by colony hybridization. To facilitate sequence analysis, two *Eco*RI fragments of 1.6 kb and 1.1 kb from the 11-kb *Sma* I subclone were filled in by using the Klenow fragment of DNA polymerase I, purified by polyacrylamide gel electrophoresis, and blunt-end-ligated into the *Pvu* II site of the vector. Several clones were tested for the presence of 1.6-kb and 1.1-kb inserts by restriction analysis of isolated plasmids.

DNA sequence analysis was carried out as described by Maxam and Gilbert (16).

RESULTS AND DISCUSSION

**Isolation and Characterization of Factor B cDNA Clones.** Synthetic oligonucleotides have been used successfully as primers of cDNA synthesis (27) and as specific hybridization probes in the detection and characterization of recombinant DNA molecules (14, 18, 19, 28). This approach was adopted to isolate cDNA clones corresponding to factor B and an oligonucleotide was synthesized against a region of the factor B sequence with the least ambiguity in codon usage. The sequence chosen was Met-Val-Trp-Glu-His, corresponding to positions 221-225 of Bb (6), and a 14-base mixture of eight synthetic oligonucleotides,



was synthesized. The oligonucleotide mix was phosphorylated




FIG. 1. Analysis of cDNA products synthesized from 18S RNA by using the 14-base oligonucleotide mix as primer. (a) The products of the reaction were run under denaturing conditions on a 3% polyacrylamide/urea gel, and the band indicated by the arrow was recovered for sequence analysis. Numbers represent size standards. (b) Schematic representation of the priming reaction and the sequence of 30 bases determined from the 5' end of the cDNA product running at  $\approx 1,560$  bases. The derived amino acid sequence agrees with the known amino acid sequence of this portion of Bb (6). The sequence underlined was used to synthesize a unique 17-base oligonucleotide probe.

at the 5' OH and was used as a primer to synthesize cDNA from the 18S fraction of human liver RNA. The reaction products were analyzed under denaturing conditions on a 3% polyacrylamide gel, and a prominent band at  $\approx 1,560$  bases was visualized (Fig. 1). This band appeared to be a strong candidate for factor B cDNA, as the expected product based on the known protein sequence data would be at least 1,425 bases long (Fig. 1). Sufficient radioactivity ( $\approx 3,000$  cpm) was contained in the band to allow elution and sequence analysis of the 5' end by the Maxam and Gilbert technique. The sequence of 30 bases was determined, enough to confirm that this band did indeed




FIG. 2. Nucleotide sequence of the FB1 cDNA insert. (Upper) Position of the cloned cDNA inserts FB1 and FB2 in relation to factor B. (Lower) The nucleotide sequence was determined on end-labeled restriction fragments isolated from polyacrylamide gels (16). The sequence complementary to the 17-base oligonucleotide probe is underlined.

correspond to factor B cDNA primed by using the 14-base oligonucleotide mix (Fig. 1).

The sequence underlined in Fig. 1 was used to synthesize a unique 17-base oligonucleotide probe. The probe was end-labeled and used to screen, by colony hybridization,  $\approx 30,000$  clones from an *Alu* I restriction fragment library of human liver cDNA cloned in the *Pvu* II site of the plasmid vector pAT153/*Pvu* II/8 (18). Two positive clones, FB1 and FB2, were identified over background after washes at 46°C and 55°C. The sequences of the cloned inserts were determined by the Maxam and Gilbert procedure. Clone FB1 contains an insert of 515 bp and codes for amino acids 80–250 of Bb, whereas clone FB2

contains an insert of 429 bp and codes for amino acids 109–250 (Fig. 2). The insert of clone FB1 is a partial digest product having an *Alu* I site at position 86 and contains within it the complete sequence of clone FB2. The amino acid sequence derived from the nucleotide sequence agrees exactly with the published amino acid sequence of Bb (6). It also confirms the assignment of an asparagine residue at position 119 of the protein sequence.

**Isolation and Characterization of Factor B Genomic Clones.** Initial screening of  $\approx 200,000$  clones from a human genomic DNA cosmid library constructed by F. G. Grosveld (21) using the nick-translated FB1 cDNA insert as probe resulted in the

D H K L K S G T N T K K A L G A V Y S M M S W P D D V P P E G W N R T  
 CTCTCCCTCTCCACAGACCACAAGTTGAAGTCAGGGACTAACACCAAGAAGGCCCTCCAGGCAGTGTACAGCATGATGAGCTGGCCAGATGACGTCCCTCTGAAGGCTGGAACCGCAC  
 10 20 30 40 50 60 70 80 90 100 110 120

R H V I I L M T D  
 CCGCATGTGTCATCCTCATGACTGATGGTCAGAAGGGACCTCTCTCTGTCCCAGCCCTCCCACCTTCTCAGACCAGCATGTGGCCCTTAAGTCCACTTGTAACTATAACCATGGT  
 130 140 150 160 170 180 190 200 210 220 230 240

TGGGGCCCTGAATGTGACTCATAGCTGGCTGTTTCATCTCTCTGTGACCCCTTCATAAGBAATTCTTCTAAGCCCTGTGATCAACTATCTCTAACCCCTCTCAACTTGTCTCACCCCTGCC  
 250 260 270 280 290 300 310 320 330 340 350 360

G L H N M G G D P I T U I D E I R  
 ATGTGATCCCTGCCTTAGCCAGTTTATCTTCTTATCTCTACCCCTCATGGTCTGTCTCTCTGCAGGATTGCACAACATGGGCGGGGACCCCAATTACTGTCAATTGATGAGATCCGG  
 370 380 390 400 410 420 430 440 450 460 470 480

D L L Y I G K D R K N P R E D Y L  
 GACTTGTATACATTGGCAAGGATCGCAAAAACCAAGGGAGGATTATCTGGGTGAGTAACCTGCCTAGGACCCAGCACCCCACTTCTCTCAGGGCTTGGACCCTCATCTTCTTTTAT  
 490 500 510 520 530 540 550 560 570 580 590 600

D U Y U F G V G P L V N G V N I N A L A S K K D N E G H V F K V K D M E N L  
 CCCTCAGATGTCTATGTGTTGGGGTGGGGCTTTGGTGAACCAAGTGAACATCAATGCTTTGGCTTCCAAGAAAGACAATGAGCAACATGTGTTCAAAGTCAAGGATATGGAAAACCTG  
 610 620 630 640 650 660 670 680 690 700 710 720

E D U F Y G M I  
 GAAGATGTTTCTACCAAAATGATCGGTAGGGAGATACAAGGGAAATAAGAACACAACCTCTCTCAGGTTCCCTGAAAGTAAATTCATTCTTCTCTACACCTGAAGCTCTAGTTGCCTGGA  
 730 740 750 760 770 780 790 800 810 820 830 840

AAGCCTTCTTCATCTCTCTCTCTACCTCAGTGTCACTATTCTTGTTCCTGGCACTGTTCACCTTAACCTTAGAATCACAGAGCTCTGAGCACTTCAGAGATCTTCTACAGTCTTACA  
 850 860 870 880 890 900 910 920 930 940 950 960

TTTGACACGTGGAACAGAAAGCCAAAGGAGGTCAAGGGACAGCAAGTGTAGCAACAAGGGTGGGCTTGAAAACAGCCAGGCCCTGACAGCTTGATCCCAAGTCTTTCCCTTTTCAGTCC  
 970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080


ACCATAGCAGTCTTCTCTAACACAGGGAACAATAACCCGTGGTCTTTCCTTTCTCTTTTGGGCTTTGCTCCCATAGACTCTACCCAAAGGCTGCTGCCATTTGGGAATGAAGT  
 1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200

D E S G S L S L C G M V W E H R K G T D Y H K G P W G A  
 GTTCCGAGTTTTCAGCACATTCTCTCTCTGCCAGATGAAAGCCAGTCTCTGAGTCTGTGGCATGGTTTGGGAACACAGGAAGGTTCCGATTACCACAAGCACCATGGCAGGCCA  
 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320

K I S V I  
 AGATCTCAGTCAATTGTAAGCACAGAATCCAGTAGTGGGGACTTGGGGAGGTTGAGGTCAAGGTGAAATGGGAGTAGGGGAAGGAAAAAATGGCCATAAGAGATGGTGGTTTGTGAAAGT  
 1330 1340 1350 1360 1370 1380 1390 1400 1410 1420 1430 1440

R P S K G H E S C M G A V V S E Y F U L T A A H C F T U D  
 TGAGCTTCCCTCTCTACTGTTGTGTCACCCAGCGCCCTTCAAAGGGACACAGAGCTGTATGGGGCTGTGGTGTCTGAGTACTTTGTGCTGACAGCAGCACCATTGTTTCTACTGTGGATG  
 1450 1460 1470 1480 1490 1500 1510 1520 1530 1540 1550 1560

D K E H S I K V S V  
 ACAAGGAACTCAATCAAGGTGAGGTAGGTAAAGGATGCAACTGAAGGTCCTGGGCTGCACCTATGCTCTCCAGCAACACCTCCCACTTCTACAGATCCTACACTCCACCCATCCTC  
 1570 1580 1590 1600 1610 1620 1630 1640 1650 1660 1670 1680



(Fig. 3 continues on the next page.)

isolation of three positive clones. Comparison of the patterns of restriction fragments showed that two of the three cosmids, which had inserts of  $\approx 40$  kb, were identical. The third cosmid had common restriction enzyme sites with the first two but appeared to have a 2-kb deletion in the internal 4.3-kb *Bam*HI fragment spanning the *Cla* I site (Fig. 3). Screening of  $\approx 200,000$  clones from a second cosmid library constructed by F. G. Grosveld resulted in the isolation of one further positive clone. This clone, which had an insert of  $\approx 35$  kb, extended the other three by 7 kb at the 3' end. Thus, the total length of genomic DNA represented in the cosmids is  $\approx 47$  kb (Fig. 3). Southern blot analysis shows that the factor B cDNA probe hybridizes to restriction fragments derived from the middle of this region (Fig. 3). No other sequences corresponding to the FBI cDNA probe were detected in this analysis, suggesting the presence of only one factor B gene.

In order to study the gene in greater detail, the 0.4-kb and 2.6-kb *Bgl* II fragments and the 11-kb *Sma* I fragment found

to hybridize with the FBI cDNA probe were subcloned and characterized by DNA sequence analysis. Various restriction enzyme digests of the subclones were used to generate fragments for sequence determination, and fragments labeled at both ends were either digested with another restriction enzyme or subjected to strand separation. In all cases, overlapping sequences were obtained for restriction sites used to generate sequence. This has allowed the almost complete structure of the *Bb* portion of the factor B gene to be determined. The 3.3 kb of continuous sequence presented in Fig. 3 comprises the entire 3' end of the gene coding for amino acids 87-505 of Bb and the complete 3'-untranslated region. The sequence of the 3'-untranslated region agrees with that found by Woods *et al.* (14) in one of their cDNA clones except at positions 3,223 and 3,230. The locations of the intron/exon boundaries were determined from comparison of the possible translation products and the published amino acid sequence of Bb (6). In all cases, the nucleotide sequence at the 5' end of an intron showed the splice




FIG. 3. (Upper Left and Right) Nucleotide sequence of 3.3 kb of DNA that encodes residues 87-505 of Bb and the 3' untranslated region of the gene. (Lower) Partial restriction map of the genomic DNA represented in the cosmid clones. The map was prepared by restriction digests of the DNA and separation of the fragments on agarose gels. Southern blot analysis was carried out as described. The region of the DNA to which the FBI cDNA probe hybridizes is indicated by a solid box. The expanded region of the map shows the 4.4-kb *Hind*III fragment that contains the *Bb* portion of the gene. The intron/exon organization was determined by DNA sequence analysis. The numbering for the amino acids that lie at either end of an exon is taken from the published sequence of Bb (6). Restriction enzyme sites: B, *Bgl* II; C, *Cla* I; E, *Eco*RI; F, *Hin*I; H, *Hind*III; Hp, *Hpa* I; K, *Kpn* I; M, *Bam*HI; Sa, *Sal* I; S, *Sma* I; and X, *Xho* I.

signal G-T, and at the 3' end, the splice signal A-G (29). No discrepancies were found between the amino acid sequence derived from the nucleotide sequence and the published amino acid sequence (6).

Sequence analysis around the *Hind*III site (Fig. 3) in the 2.6-kb *Bgl* II subclone has shown that this restriction enzyme site lies about 60 bp from the 3' end of the exon coding for the COOH-terminal region of the Ba fragment (result not shown). Thus, the Bb portion of the factor B gene is contained in the 4.4-kb *Hind*III fragment (Fig. 3) and is about 4 kb in length. Because the *Hind*III site lies about 21 kb from the 5' end of the cosmid DNA, it is likely that the complete gene is represented in the DNA isolated.

**Structure of the Gene.** Factor B is an unusual serine proteinase with a catalytic chain of approximately twice the size of other serine proteinases (6). The 3.3 kb of DNA sequence obtained (Fig. 3) encodes 11 exons corresponding to amino acids 87–505 of Bb. The first three exons are of similar size coding for 44, 34, and 46 amino acids, respectively, which lie in the NH<sub>2</sub>-terminal half of Bb. The fourth exon, encoding 33 amino acids, specifies a region of the molecule that, in other serine proteinases, contains the peptide bond that is cleaved during activation.

Residues 222–505 of Bb correspond to that portion of the molecule homologous to the catalytic chain of other serine proteinases. The structure of this region of the gene, which is 2 kb in length, is shown schematically in Fig. 4. It is split into eight exons separated by introns of various lengths and with the codon for residue 222 lying 33 bases from the 5' end of the first exon. The catalytically important residues histidine-267, aspartic acid-317, and serine-440 are found in separate exons (Fig. 4). The exon specifying the primary binding site, residues 438–443 (Gly-Asp-Ser-Gly-Gly-Pro), and containing serine-440 is only 50 bp long. This exon is separated by a 270-nucleotide-long intron from the exon containing the secondary binding site corresponding to residues 459–461 (Ser-Trp-Gly) and by an 81-nucleotide-long intron from the exon that contains the amino acid residue determining specificity in the binding pocket, probably aspartic acid-432 (6) (Fig. 4).

Each functionally important part of the active site is contained in a separate exon, and, because none are functionally independent, they must have been conserved in a definite relationship to each other throughout evolution. This also appears to be the case with chymotrypsinogen and trypsinogen, as the three catalytically important residues His, Asp, and Ser and the amino acid conferring specificity at the active site are all contained in separate exons (30). It has been suggested that the intron/exon structure of a gene may be a mechanism for increasing the rate of evolution and that recombination within introns could reassort protein functions to produce novel pro-




FIG. 4. Organization of exons in the serine proteinase domain of Bb. Residues 222–505 of Bb correspond to the catalytic chain of other serine proteinases (6). The region of the gene encoding these amino acids is 2 kb in length and comprises eight exons, with the codon for residue 222 lying 33 bp from the 5' end of the first exon. Exons that contain the catalytically important amino acids histidine-267, aspartic acid-317, and serine-440 are shown, as is the exon that contains the amino acid conferring specificity in the binding pocket and the exon containing the secondary binding site.

teins from parts of existing ones (31, 32). If the functionally important parts of the catalytic sites of other serine proteinases are also found to lie on separate exons, such an arrangement may have facilitated the interchange of specificity-determining sequences and played a role in the emergence of the many serine proteinases which exist.

We thank Professor G. G. Brownlee for generous provision of facilities and for his help and advice throughout this work. We also thank Dr. M. C. Carroll for providing the human liver cDNA library; Dr. F. G. Grosveld for providing the cosmid libraries; Mr. Keith Gould for help in synthesis of oligonucleotides; Drs. C. Blake, J. Gagnon, M. C. Carroll, and D. H. Bentley for helpful discussion; and Miss N. J. Janjua for excellent technical assistance.

- Barnstaple, C. J., Jones, E. A. & Bodmer, W. F. (1979) in *Defense and Recognition II B, Cellular Aspects*, MTP International Review of Biochemistry, ed. Lennox, E. S. (University Park Press, Baltimore), Vol. 22, pp. 151–224.
- Alper, C. A. (1981) in *The Role of the Major Histocompatibility Complex in Immunobiology*, ed. Dorf, M. E. (Garland, New York), pp. 173–220.
- Reid, K. B. M. & Porter, R. R. (1981) *Annu. Rev. Biochem.* **50**, 433–464.
- Kerr, M. A. (1979) *Biochem. J.* **183**, 615–622.
- Medicus, R. G., Götze, O. & Müller-Eberhard, H. J. (1976) *Scand. J. Immunol.* **5**, 1049–1055.
- Christie, D. L. & Gagnon, J. (1983) *Biochem. J.* **209**, 61–70.
- Alper, C. A., Boenisch, T. & Watson, L. (1972) *J. Exp. Med.* **135**, 68–80.
- Ploegh, H. L., Orr, H. T. & Strominger, J. L. (1980) *Proc. Natl. Acad. Sci. USA* **77**, 6081–6085.
- Sood, A. K., Pereira, D. & Weissman, S. M. (1981) *Proc. Natl. Acad. Sci. USA* **78**, 616–620.
- Malissen, M., Malissen, B. & Jordan, B. R. (1982) *Proc. Natl. Acad. Sci. USA* **79**, 893–897.
- Lee, J. S., Trowsdale, J. & Bodmer, W. F. (1982) *Proc. Natl. Acad. Sci. USA* **79**, 545–549.
- Lee, J. S., Trowsdale, J., Travers, P. J., Carey, J., Grosveld, F., Jenkins, J. & Bodmer, W. F. (1982) *Nature (London)* **299**, 750–752.
- Korman, A. J., Auffrey, C., Schamboeck, A. & Strominger, J. L. (1982) *Proc. Natl. Acad. Sci. USA* **79**, 6013–6017.
- Woods, D. E., Markham, A. F., Ricker, A. T., Goldberger, G. & Colten, H. (1982) *Proc. Natl. Acad. Sci. USA* **79**, 5661–5665.
- Duckworth, M. L., Gait, M. J., Golet, P., Hong, G. F., Singh, M. & Titmas, R. C. (1981) *Nucleic Acids Res.* **9**, 1691–1706.
- Maxam, A. M. & Gilbert, W. (1980) *Methods Enzymol.* **65**, 499–560.
- Wickens, M. P., Buell, G. N. & Schimke, R. T. (1978) *J. Biol. Chem.* **253**, 2483–2495.
- Carroll, M. C. & Porter, R. R. (1983) *Proc. Natl. Acad. Sci. USA* **80**, 264–267.
- Suggs, S. V., Wallace, R. B., Hirose, T., Kawashima, E. H. & Itakura, K. (1981) *Proc. Natl. Acad. Sci. USA* **78**, 6613–6617.
- Gergen, J. P., Stern, R. H. & Websink, P. C. (1979) *Nucleic Acids Res.* **7**, 2115–2136.
- Grosveld, F. G., Lund, T., Murray, E. J., Mellor, A. L., Dahl, H. H. M. & Flavell, R. A. (1982) *Nucleic Acids Res.* **10**, 6715–6732.
- Grosveld, F. G., Dahl, H. H. M., de Boer, E. & Flavell, R. A. (1981) *Gene* **13**, 227–237.
- Bernards, R. & Flavell, R. A. (1980) *Nucleic Acids Res.* **8**, 1521–1534.
- Rigby, P. W. J., Dieckmann, M., Rhodes, C. & Berg, P. (1977) *J. Mol. Biol.* **113**, 237–251.
- Birnboim, H. C. & Doly, J. (1979) *Nucleic Acids Res.* **7**, 1513–1523.
- Wahl, G. M., Stern, M. & Stark, G. R. (1979) *Proc. Natl. Acad. Sci. USA* **76**, 3683–3687.
- Agarwal, K. L., Brunstedt, J. & Noyes, B. E. (1981) *J. Biol. Chem.* **256**, 1023–1028.
- Choo, K. H., Gould, K. G., Rees, D. J. G. & Brownlee, G. G. (1982) *Nature (London)* **299**, 178–180.
- Mount, S. M. (1982) *Nucleic Acids Res.* **10**, 459–472.
- Craik, C. S., Sprang, S., Fletterick, R. & Rutter, W. J. (1982) *Nature (London)* **299**, 180–182.
- Gilbert, W. (1978) *Nature (London)* **271**, 501.
- Blake, C. (1978) *Nature (London)* **273**, 267.